247 related articles for article (PubMed ID: 9737641)
1. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.
von Keutz E; Schlüter G
Am J Cardiol; 1998 Aug; 82(4B):11J-17J. PubMed ID: 9737641
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical pharmacology of cerivastatin.
Bischoff H; Heller AH
Am J Cardiol; 1998 Aug; 82(4B):18J-25J. PubMed ID: 9737642
[TBL] [Abstract][Full Text] [Related]
3. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor.
Bischoff H; Angerbauer R; Bender J; Bischoff E; Faggiotto A; Petzinna D; Pfitzner J; Porter MC; Schmidt D; Thomas G
Atherosclerosis; 1997 Nov; 135(1):119-30. PubMed ID: 9395280
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
Davignon J; Hanefeld M; Nakaya N; Hunninghake DB; Insull W; Ose L
Am J Cardiol; 1998 Aug; 82(4B):32J-39J. PubMed ID: 9737644
[TBL] [Abstract][Full Text] [Related]
5. Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition.
Bischoff H; Angerbauer R; Boberg M; Petzinna D; Schmidt D; Steinke W; Thomas G
Atherosclerosis; 1998 Sep; 139 Suppl 1():S7-13. PubMed ID: 9811153
[TBL] [Abstract][Full Text] [Related]
6. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
7. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
Stein E
Am J Cardiol; 1998 Aug; 82(4B):40J-46J. PubMed ID: 9737645
[TBL] [Abstract][Full Text] [Related]
8. Reduction of plasma cholesterol levels and induction of hepatic LDL receptor by cerivastatin sodium (CAS 143201-11-0, BAY w 6228), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in dogs.
Yasunobu Y; Hayashi K; Shingu T; Nomura K; Ohkura Y; Tanaka K; Kuga Y; Nomura S; Ohtani H; Nishimura T; Matsuura H; Kajiyama G
Cardiovasc Drugs Ther; 1997 Sep; 11(4):567-74. PubMed ID: 9358961
[TBL] [Abstract][Full Text] [Related]
9. Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety.
Stein E
Atherosclerosis; 1998 Sep; 139 Suppl 1():S15-22. PubMed ID: 9811154
[TBL] [Abstract][Full Text] [Related]
10. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
Stein EA
Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
[TBL] [Abstract][Full Text] [Related]
11. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity.
Seachrist JL; Loi CM; Evans MG; Criswell KA; Rothwell CE
Toxicol Sci; 2005 Dec; 88(2):551-61. PubMed ID: 16141437
[TBL] [Abstract][Full Text] [Related]
12. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Mück W; Ochmann K; Rohde G; Unger S; Kuhlmann J
Eur J Clin Pharmacol; 1998 Feb; 53(6):469-73. PubMed ID: 9551706
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
[TBL] [Abstract][Full Text] [Related]
14. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
[TBL] [Abstract][Full Text] [Related]
15. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
[TBL] [Abstract][Full Text] [Related]
16. [Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis].
Zeitlinger M; Müller M
Wien Med Wochenschr; 2003; 153(11-12):250-4. PubMed ID: 12879633
[TBL] [Abstract][Full Text] [Related]
17. Preventive effects of bicarbonate on cerivastatin-induced apoptosis.
Kobayashi M; Kaido F; Kagawa T; Itagaki S; Hirano T; Iseki K
Int J Pharm; 2007 Aug; 341(1-2):181-8. PubMed ID: 17553641
[TBL] [Abstract][Full Text] [Related]
18. Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats.
Obayashi H; Nezu Y; Yokota H; Kiyosawa N; Mori K; Maeda N; Tani Y; Manabe S; Sanbuissho A
J Toxicol Sci; 2011 Aug; 36(4):445-52. PubMed ID: 21804308
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of cerivastatin: phase IIa dose-ranging and dose-scheduling studies.
Hunninghake DB
Am J Cardiol; 1998 Aug; 82(4B):26J-31J. PubMed ID: 9737643
[TBL] [Abstract][Full Text] [Related]
20. The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys.
Hartman HA; Myers LA; Evans M; Robison RL; Engstrom RG; Tse FL
Fundam Appl Toxicol; 1996 Jan; 29(1):48-62. PubMed ID: 8838639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
